ライフサイエンスコーパス: Ga

1 Ga(2)O(3) has an enormous band gap of 4.8 eV, which make

2 Ga-68 Prostate-Specific Membrane Antigen PET/CT is a new

3 vents (ranging from 3.7 to 3.6 Ga to ca. 2.0 Ga) interacting with changing ocean/base levels.

4 ars, with much of this record dating 3.6-3.0 Ga.

5 te differentiation in the Hadean (4.6 to 4.0 Ga) has been provided by (142)Nd/(144)Nd measurements of

6 We present field relationships from the 1.07-Ga Pikes Peak batholith in Colorado that constrain the p

7 es from an early differentiated mantle (>4.1 Ga ago) are preserved in the modern mantle.

8 A minority of the grains have ages >1 Ga.

9 a lower formation temperature for the Ca(12)Ga(14)O(33) analogue compared to Ca(12)Al(14)O(33) synth

10 Ca(12)Ga(14)O(33) was successfully synthesized using a wet che

11 tion (ca. 1000 m) between ca. 3.6 Ga and 3.2 Ga and soon afterwards disappeared, thereby indicating a

12 y/heterogeneity in the mantle for the last 2 Ga.

13 (0.9) O(1.95) and perovskite La(0.8) Sr(0.2) Ga(0.8) Mg(0.2) O(2.55) ) with a high concentration of o

14 o the polar "114"-type structure of CaBaZn(2)Ga(2)O(7) leads to an unexpected cell volume expansion o

15 cell volume expansion of CaBa(1-x)Pb(x)Zn(2)Ga(2)O(7) (0 <= x <= 1), which is a unique structural ph

16 tion of the unit cell for CaBa(1-x)Pb(x)Zn(2)Ga(2)O(7) is due to the combination of the high stereoch

17 of Pb(2+) with the extremely strained [Zn(2)Ga(2)O(7)](4-) framework along the c-axis.

18 hundreds of millions of years until the ~2.4 Ga Great Oxidation Event.

19 e coeval large igneous province aged 2.2-2.4 Ga that operated under the Snowball Earth glaciation con

20 L) to achieve the same composition as Al(0.4)Ga(0.07)In(0.53)As quaternary random alloy (RA).

21 tmospheric O(2) from accumulating until ~2.5 Ga with >=95% probability.

22 lso confirmed experimentally against a Ni(5) Ga(3) intermetallic catalyst with partially isolated Ni

23 r (an air bridge) within a thin-film In(0.53)Ga(0.47)As cell.

24 impact ionization characteristics of In(0.53)Ga(0.47)As/Al(0.48)In(0.52)As superlattice avalanche pho

25 se in elevation (ca. 1000 m) between ca. 3.6 Ga and 3.2 Ga and soon afterwards disappeared, thereby i

26 dic flooding events (ranging from 3.7 to 3.6 Ga to ca. 2.0 Ga) interacting with changing ocean/base l

27 (68)Ga-DOTA-Siglec-9 was rapidly cleared from the blood circ

28 (68)Ga-DOTATOC-avid tumor lesions were semiautomatically del

29 (68)Ga-FAPI PET/CT seems to be a highly promising imaging ag

30 (68)Ga-fibroblast activation protein inhibitors (FAPIs) 2, 4

31 (68)Ga-Ga-NODAGA-IL2 uptake in liver and kidney was higher t

32 (68)Ga-labeled arginine-glycine-aspartate tripeptide sequenc

33 (68)Ga-labeled chelator-linked FAP inhibitors (FAPIs) have b

34 (68)Ga-labeled prostate-specific membrane antigen (PSMA) PET

35 (68)Ga-labeled urea-based inhibitors of the prostate-specifi

36 (68)Ga-NeoBOMB1 (3 MBq/kg of body weight) was injected intra

37 (68)Ga-NeoBOMB1 was prepared using a kit procedure with a li

38 ison matched 160 (18)F-rhPSMA-7 with 160 (68)Ga-PSMA-11 PET/CT studies for primary staging (n = 33) a

39 e PET radioligand (68)Ga-DO3A-VS-Tuna-2 ((68)Ga-Tuna-2) was developed to yield a noninvasive imaging

40 ((18)F) fluorodeoxyglucose, gallium 68 ((68)Ga) tetraazacyclododecane tetraacetic acid octreotate (o

41 A (68)Ga-labeled peptide of Siglec-9, (68)Ga-DOTA-Siglec-9, holds promise as a novel PET tracer fo

42 ratio [HR], 0.45; P = 0.024), whereas a (68)Ga-DOTATOC-avid tumor volume higher than 578 cm(3) (75th

43 A (68)Ga-labeled peptide of Siglec-9, (68)Ga-DOTA-Siglec-9, ho

44 hods: We report management changes after (68)Ga-PSMA PET, a secondary endpoint of a prospective multi

45 d) who underwent Glu-NH-CO-NH-Lys-(Ahx)-[(68)Ga(HBED-CC)] ((68)Ga-PSMA11) PET/MRI for initial staging

46 Also, (68)Ga-PSMA PET/CT positivity was correlated with clinical p

47 (64)Cu- and (68)Ga-DOTA-ECL1i were compared in an ischemia-reperfusion i

48 itative assessment of (68)Ga-DOTATOC and (68)Ga-DOTATATE tumor uptake and as a therapy monitoring too

49 of 0.98 and 0.93 for (68)Ga-DOTATOC and (68)Ga-DOTATATE, respectively.

50 Uptake of (68)Ga-FAPI-04 and (68)Ga-FAPI-46 was quantified by SUV(max) and SUV(mean) Afte

51 n: Production of (18)F-AlF-RESCA-IL2 and (68)Ga-Ga-NODAGA-IL2 is simpler and faster than that of (18)

52 atients receiving (18)F-fluciclovine and (68)Ga-prostate-specific membrane antigen ((68)Ga-PSMA-11) f

53 The SUV(max) of (18)F-rhPSMA-7 and (68)Ga-PSMA-11 did not differ (P > 0.05) in local recurrence

54 concordance between (18)F-PSMA-1007 and (68)Ga-PSMA-11 for detection of intraprostatic lesions.

55 udy showed that both (18)F-PSMA-1007 and (68)Ga-PSMA-11 identify all dominant prostatic lesions in pa

56 sults: In total, (18)F-PSMA-1007 PET and (68)Ga-PSMA-11 PET revealed 369 and 178 PSMA-ligand-positive

57 Results: (18)F-rhPSMA-7 and (68)Ga-PSMA-11 PET revealed 566 and 289 PSMA ligand-positive

58 Methods: All (18)F-fluciclovine and (68)Ga-PSMA-11 PET studies performed at the University of Ca

59 h-risk PCa underwent (18)F-PSMA-1007 and (68)Ga-PSMA-11 PET/CT within 15 d.

60 4 can be labeled with both (18)F-AlF and (68)Ga.

61 t compared with [(64)Cu]Cu-DOTATATE and [(68)Ga]Ga-DOTATATE for PET imaging of somatostatin receptor-

62 those for both [(64)Cu]Cu-DOTATATE and [(68)Ga]Ga-DOTATATE.

63 8)Ga prostate-specific membrane antigen ((68)Ga-PSMA) is a promising tool to improve the harvest rate

64 8)Ga-prostate-specific membrane antigen ((68)Ga-PSMA-11) for biochemically recurrent prostate cancer

65 pecific membrane antigen (PSMA), such as (68)Ga-PSMA-11, are promising small molecules for targeting

66 surements corresponded to a lesion-based (68)Ga-PSMA-11 PET lesion detection rate of 80%, 93%, 89%, 2

67 cer patients should be revisited because (68)Ga-PSMA-11 PET/CT may provide additional information for

68 nhanced CT (ceCT) for TNM staging before (68)Ga-FAPI PET/CT imaging.

69 In tumor-positive biopsies, (68)Ga-PSMA uptake was significantly higher (P = 0.008), whe

70 f bone metastases detected by total-body (68)Ga-prostate-specific membrane antigen (PSMA)-11 PET/CT a

71 a under the curve of 0.84 and 0.70, both (68)Ga-PSMA uptake (SUV(max)) and radiodensity (mean Hounsfi

72 tic LGT tumors were reliably detected by (68)Ga-FAPI PET/CT, leading to relevant changes in TNM statu

73 arget volume delineation was improved by (68)Ga-FAPI PET/CT.

74 -IMP288 bispecific antibody, followed by (68)Ga-IMP288, is a potentially sensitive theranostic imagin

75 th quantification of CXCR4 expression by (68)Ga-pentixafor PET in vivo before initiation of treatment

76 s, sites of recurrence were clarified by (68)Ga-PSMA PET, and disease localization translated into ma

77 high-risk PCa patients primary-staged by (68)Ga-PSMA PET/CT.

78 NaF PET (n = 52, 35%), were prevented by (68)Ga-PSMA PET; 73 tests, mostly biopsies (n = 44, 60%) as

79 lu-NH-CO-NH-Lys-(Ahx)-[(68)Ga(HBED-CC)] ((68)Ga-PSMA11) PET/MRI for initial staging of biopsy-proven

80 Results: Compared with ceCT, (68)Ga-FAPI PET/CT results led to changes in TNM staging in

81 To characterize (68)Ga-FAPI uptake over time, additional scans after 10 or 1

82 ifornia San Francisco (UCSF) codeveloped (68)Ga-PSMA-11 by conducting a bicentric pivotal phase 3 cli

83 mico classification and, second, compare (68)Ga-PSMA PET/CT findings with radical prostatectomy and p

84 ake and the detection efficacy comparing (68)Ga-PSMA-11 PET/CT and (18)F-PSMA-1007 PET/CT in recurren

85 Conclusion: (68)Ga-FAPI PET/CT led to restaging in half of the patients

86 Conclusion: (68)Ga-pentixafor PET represents a novel diagnostic tool for

87 Conclusion: (68)Ga-PSMA PET/CT showed promise for early detection of rec

88 Conclusion: (68)Ga-PSMA-11 dose reduction is not feasible without a nega

89 l variables, patients with corresponding (68)Ga-PSMA-11 PET/CT scans were matched.

90 s attributed to a benign origin than did (68)Ga-PSMA-11 PET (245 vs. 52 lesions, respectively).

91 traacetic acid octreotate (or DOTATATE), (68)Ga prostate-specific membrane antigen, and (18)F-flucicl

92 We examined the performance of dynamic (68)Ga-PSMA-11 PET/CT (DPSMA) for the evaluation of localize

93 ntrareader reproducibility in evaluating (68)Ga-PSMA11 PET, there are some factors causing interreade

94 oduce the identical (68)Ga-labeled (19)F-(68)Ga-rhPSMA tracers, and the possibility to extend this co

95 al evaluation of [(68)Ga]Ga-NOTA-folate ((68)Ga-FOL).

96 Pearson correlation of 0.98 and 0.93 for (68)Ga-DOTATOC and (68)Ga-DOTATATE, respectively.

97 describes the start-to-finish story for (68)Ga-DOTATOC, including a description of the clinical tria

98 8)F-FAPI-74 was 1.4 +/- 0.2 mSv, and for (68)Ga-FAPI-74 it was 1.6 mSv.

99 8)F-FAPI-74 and a proof of mechanism for (68)Ga-FAPI-74 labeled at ambient temperature.

100 useful lower limit of injected dose for (68)Ga-prostate-specific membrane antigen (PSMA)-11 PET/CT i

101 positive, inconclusive, or negative for (68)Ga-PSMA uptake, 70%, 64%, and 36% of biopsies were tumor

102 ositivity rate was consistently high for (68)Ga-PSMA-11 and (18)F-rhPSMA-7.

103 for (18)F-PSMA-1007 PET and 126/178 for (68)Ga-PSMA-11 PET).

104 -PSMA-1007 PET and 29%, 42%, and 27% for (68)Ga-PSMA-11 PET, respectively.

105 higher for (18)F-PSMA-1007 PET than for (68)Ga-PSMA-11 PET.

106 hPSMA-7 is similar to published data for (68)Ga-PSMA-11.

107 hereas (68)Ga was obtained from a (68)Ge/(68)Ga generator.

108 g a kit procedure with a licensed (68)Ge/(68)Ga generator.

109 Conclusion: Normal baseline IBI and high (68)Ga-DOTATOC tumor uptake predict better outcome in NET pa

110 Most importantly, however, (68)Ga-DOTA-Siglec-9 was comparable to (18)F-FDG in detectin

111 y; range, 43-81 y) who underwent hybrid (68)Ga-DOTA PET/MRI at 3 T between January 2017 and July 201

112 the possibility to produce the identical (68)Ga-labeled (19)F-(68)Ga-rhPSMA tracers, and the possibil

113 the total body (from vertex to toes) in (68)Ga-PSMA-11 PET/CT imaging revealed additional bone lesio

114 Increased (68)Ga-PSMA-11 tracer uptake and intratumoral retention corr

115 creased injected activity, and increased (68)Ga-PSMA-11 uptake time were significantly associated wit

116 ing using (68)Ga-labeled FAP-inhibitors ((68)Ga-FAPI PET/CT) in 19 patients with PDAC (7 primary, 12

117 Interim (68)Ga-DOTATOC PET does not provide information for treatmen

118 lity of pretherapeutic and early interim (68)Ga-DOTATOC PET tumor uptake and volumetric parameters an

119 t 5 patients also received intraarterial (68)Ga-DOTATOC and underwent PET/CT.

120 erwent baseline PET/CT using intravenous (68)Ga-DOTATOC.

121 elation between uptake of the PET ligand (68)Ga-NOTA-AE105, targeting the urokinase-type plasminogen

122 Methods: (68)Ga-FAPI PET/CT was performed on a cohort of 22 patients

123 Methods: (68)Ga-PSMA-11 PET/CT was performed on 11 patients.

124 Moreover, (68)Ga-PSMA PET/CT findings were compared with histology fin

125 Multiphasic (68)Ga-PSMA PET/CT led to a better determination of equivoca

126 g was identified, in vivo, using a novel (68)Ga-labeled GLP-1r positron-emitting probe that supplied

127 However, the short half-life of (68)Ga (68 min) creates problems with manufacture and delive

128 els, with efficacy comparable to that of (68)Ga-DOTA-ECL1i.

129 Conclusion: Intravenous injection of (68)Ga-DOTA-Siglec-9 was safe and biodistribution was favora

130 The effective radiation dose of (68)Ga-DOTA-Siglec-9 was within the same range as the effect

131 Injection of 150 MBq of (68)Ga-DOTA-Siglec-9 would expose a subject to 3.3 mSv.

132 ntravenous injection of 162 +/- 4 MBq of (68)Ga-DOTA-Siglec-9.

133 tool for semiquantitative assessment of (68)Ga-DOTATOC and (68)Ga-DOTATATE tumor uptake and as a the

134 that ultimately resulted in approval of (68)Ga-DOTATOC in August 2019.

135 Markedly elevated uptake of (68)Ga-FAPI in PDAC manifestations after 1 h was seen in mos

136 The clinical value of (68)Ga-FAPI PET/CT should be further investigated.

137 Uptake of (68)Ga-FAPI-04 and (68)Ga-FAPI-46 was quantified by SUV(max)

138 ibution and radiation dosimetry study of (68)Ga-FAPI-46 in cancer patients.

139 xamination after injection of 263 MBq of (68)Ga-FAPI-74.

140 Myocardial uptake of (68)Ga-FOL was 20-fold lower than that of (18)F-FDG.

141 e plaque-to-healthy vessel wall ratio of (68)Ga-FOL was significantly higher than that of (18)F-FDG.

142 immuno-PET after injection of 150 MBq of (68)Ga-IMP288, a histamine-succinyl-glycine peptide given af

143 n after administration of 150-250 MBq of (68)Ga-labeled FAP-specific tracers.

144 the reason for the current dominance of (68)Ga-labeled peptides and peptide-like ligands in radiopha

145 etry, and preliminary tumor targeting of (68)Ga-NeoBOMB1 in patients with advanced tyrosine-kinase in

146 d using rigid-body image registration of (68)Ga-PSMA PET/CT and interventional CT.

147 the impact of multiphasic acquisition of (68)Ga-PSMA PET/CT in the detection of recurrent prostate ca

148 he injection of comparable activities of (68)Ga-PSMA-11 obtained with the 2 different synthetic proce

149 s to evaluate the diagnostic accuracy of (68)Ga-PSMA-11 PET for osseous prostate cancer metastases an

150 udy was to evaluate the image quality of (68)Ga-PSMA-11 PET/CT (PSMA-PET) in a population of PCa pati

151 ts that aimed to determine the impact of (68)Ga-PSMA-11 PET/CT on PCa stage and management.

152 with the already high detection rate of (68)Ga-PSMA-11 PET/CT.

153 udy was to determine the success rate of (68)Ga-PSMA-guided bone biopsies for molecular diagnostics i

154 uccess rate (tumor percentage >= 30%) of (68)Ga-PSMA-guided bone biopsies.

155 ese estimates are an important aspect of (68)Ga-PSMA-HBED-CC as a quantitative imaging biomarker.

156 dy was to determine the repeatability of (68)Ga-PSMA-HBED-CC in a test-retest trial in subjects with

157 be conducted to explore the potential of (68)Ga-RGD PET/CT imaging for guiding current treatment deci

158 Binding of (68)Ga-Tuna-2 in liver and reference tissues was evaluated a

159 ds: The biodistribution and dosimetry of (68)Ga-Tuna-2 was assessed by PET/CT in 13 individuals with

160 ose per gram of tissue [%ID/g]) than of [(68)Ga]Ga-FAPI-04 (2 %ID/g).

161 synthesis and preclinical evaluation of [(68)Ga]Ga-NOTA-folate ((68)Ga-FOL).

162 In 29% of patients, all lesions on (68)Ga-PSMA PET resolved in response to treatment.

163 value, and accuracy for LNM detection on (68)Ga-PSMA PET/CT in the PLND cohort were 30.6%, 96.5%, 68.

164 23 patients and bone metastases in 5 on (68)Ga-PSMA-11 PET/MRI.

165 ctomy or biopsy), EUS, CT or MRI, and/or (68)Ga-DOTA-TATE PET/CT.

166 e the role of PSMA (i.e.,(18)F-DCFPyL or (68)Ga-PSMA-11) PET/CT imaging in patients who experience BC

167 s, 13 (22.8%) had false-positive osseous (68)Ga-PSMA-11 findings and 43 (76.8%) had true-positive oss

168 and 43 (76.8%) had true-positive osseous (68)Ga-PSMA-11 findings.

169 s; (68)Ga-FAPI-74 is comparable to other (68)Ga ligands.

170 s the effective radiation doses of other (68)Ga-labeled tracers.

171 ET has several principal advantages over (68)Ga-PSMA-11.

172 We performed (68)Ga-PSMA-11 PET/CT imaging of 10 patients with metastatic

173 We were able to produce (68)Ga-FOL with high radiochemical purity and moderate molar

174 Here, we compared the 3 radioconjugates [(68)Ga]Ga-DOTATATE, [(64)Cu]Cu-DOTATATE, and [(55)Co]Co-DOTA

175 The PET radioligand (68)Ga-DO3A-VS-Tuna-2 ((68)Ga-Tuna-2) was developed to yield

176 sults: In total, 1,502 patients received (68)Ga-PSMA-11 and 254 patients received (18)F-fluciclovine.

177 Results: (68)Ga-DOTA-Siglec-9 was well tolerated by all subjects.

178 Results: (68)Ga-Ga-NODAGA-IL2 and (18)F-AlF-RESCA-IL2 were produced w

179 Results: (68)Ga-NeoBOMB1 (50 mug) was prepared with high radiochemica

180 Results: (68)Ga-pentixafor PET showed excellent contrast with the sur

181 ern of integrin alpha(v)beta(3) Results: (68)Ga-RGD PET/CT imaging showed enhanced uptake in all AVM

182 Results: (68)Ga-Tuna-2 binding was seen primarily in the liver, which

183 with different cancers underwent serial (68)Ga-FAPI-46 PET/CT scans at 3 time points after radiotrac

184 A first analysis of simultaneous (68)Ga-prostate-specific membrane antigen (PSMA)-11 PET/MRI

185 At biopsy sites, (68)Ga-PSMA uptake was quantified using rigid-body image reg

186 Cell binding studies revealed that (68)Ga-FOL had 5.1 nM affinity for FR-beta.

187 istochemistry of the aorta revealed that (68)Ga-FOL radioactivity co-localized with Mac-3-positive ma

188 Together, these findings show that (68)Ga-FOL represents a promising new FR-beta-targeted trace

189 Blocking studies verified that (68)Ga-FOL was specific for FR.

190 difying group optimization revealed that (68)Ga-HTK03041 bearing a tranexamic acid-9-anthrylalanine a

191 Conclusion: This feasibility showed that (68)Ga-PSMA CLI is a new intraoperative imaging technique ca

192 In addition, we show that (68)Ga-PSMA-11 PET/MRI detected PSMA-positive lesions outsid

193 Conclusion: Our data confirm that (68)Ga-PSMA-11 PET/MRI has a high detection rate for recurre

194 reported for (18)F-FDG, suggesting that (68)Ga-PSMA-HBED-CC PET/CT may be useful in monitoring respo

195 out angiogenic activity, suggesting that (68)Ga-RGD PET/CT imaging can be used as a tool to quantitat

196 study was performed to demonstrate that (68)Ga-RGD PET/CT imaging can be used to quantitatively asse

197 istilled experiences associated with the (68)Ga-DOTATOC NDA process.

198 9m)Tc tracers and was lower than for the (68)Ga-labeled and (18)F-labeled agents.

199 11 PET/CT and to assess if expanding the (68)Ga-PSMA-11 PET/CT imaging field to include the vertex an

200 ion, and lower positron range than their (68)Ga-labeled counterparts.

201 Therefore, (68)Ga-PSMA PET/CT may be considered for guidance of bone bi

202 8)F-JK-PSMA-7 was at least equivalent to (68)Ga-PSMA-11.

203 ve radiation doses from the novel tracer (68)Ga-NODAGA-exendin-4 are very low for adults and children

204 maged with the CXCR4-directed PET tracer (68)Ga-pentixafor.

205 with (18)F-FDG and other (18)F tracers; (68)Ga-FAPI-74 is comparable to other (68)Ga ligands.

206 tatic spread of PCa in relation to tumor (68)Ga-PSMA uptake and the D'Amico classification and, secon

207 e cancer (PCa) cohort to date undergoing (68)Ga-prostate-specific membrane antigen (PSMA) PET/CT prim

208 (NCT01855477), 69 mPC patients underwent (68)Ga-PSMA PET/CT before bone biopsy.

209 All underwent (68)Ga-PSMA-11 PET/CT scans acquired from vertex to toes for

210 of 66 consecutive patients who underwent (68)Ga-PSMA-11 PET/MRI for biochemical recurrence with a PSA

211 th biochemical recurrence) who underwent (68)Ga-PSMA-11 PET/MRI or PET/CT examinations with osseous P

212 nts (mean age, 70.5 y old) who underwent (68)Ga-PSMA11 PET/CT because of biochemically recurrent PC.

213 All patients underwent (68)Ga-RGD PET/CT imaging 60 min after injection (mean dose,

214 All unequivocally (68)Ga-PSMA-11-positive lesions could be also detected using

215 PET using (68)Ga prostate-specific membrane antigen ((68)Ga-PSMA) is a

216 and pre- and posttreatment imaging using (68)Ga-DOTATOC PET/CT from patients treated with PRRT at the

217 s, as also shown on PET/CT imaging using (68)Ga-FAPI-46.

218 clinical impact of PET/CT imaging using (68)Ga-labeled FAP-inhibitors ((68)Ga-FAPI PET/CT) in 19 pat

219 g imaging with (18)F-fluciclovine versus (68)Ga-PSMA-11 compared with non-Hispanic White patients (od

220 Ni(p,n)(64)Cu nuclear reactions, whereas (68)Ga was obtained from a (68)Ge/(68)Ga generator.

221 In a second clinical study with (68)Ga-DOTATATE, we demonstrated comparable diagnostic image

222 related uptake and tumor positivity with (68)Ga-PSMA-11 and (18)F-rhPSMA-7 in patients with primary o

223 18)F-rhPSMA-7 vs. 32%, 24%, and 38% with (68)Ga-PSMA-11 for ganglia, bone, and unspecific lymph nodes

224 not inferior when directly compared with (68)Ga-PSMA-11 in a pilot study but indeed identified additi

225 8)F-JK-PSMA-7 was directly compared with (68)Ga-PSMA-11 PET/CT in a group of 10 patients with prostat

226 gnostic accuracy of (18)F-PSMA-1007 with (68)Ga-PSMA-11 PET/CT in the same patients presenting with n

227 In addition, all scans with (68)Ga-PSMA-11 PET/MRI-positive lesions were retrospectively

228 27 in whom PET/CT results obtained with (68)Ga-PSMA-11, (18)F-DCFPyL (2-(3-(1-carboxy-5-[(6-[(18)F]f

229 and low urinary excretion compared with (68)Ga-PSMA-11.

230 easurements for PET/CT test-retests with (68)Ga-PSMA-HBED-CC showed a wCV of 12%-14% SUV(max) and an

231 ate cancer underwent 2 PET/CT scans with (68)Ga-PSMA-HBED-CC within 14 d (mean, 6 +/- 4 d).

232 udies of [(18)F]FGlc-FAPI compared with [(68)Ga]Ga-FAPI-04 were conducted in nude mice bearing HT1080

233 a mean surface temperature of ~300 K at 2.7 Ga, which may be too high, given evidence for glaciation

234 deposition was already well established >3.7 Ga.

235 ing an episode of enhanced star formation ~7 Ga ago.

236 In this work, (71) Ga NMR spectroscopy shows the presence of [Ga(arene)(n)

237 tic features observed in both (27)Al and (71)Ga NMR spectra result from both the deviations in the po

238 The sharp (27)Al and (71)Ga resonances arise from dopants located at a highly sym

239 rties; high-resolution solid-state (1)H, (71)Ga, and (115)In NMR spectroscopy; and discrete Fourier t

240 The (71)Ga{(1)H} rotational-echo double-resonance (REDOR) NMR an

241 that their development persisted until ~1.8 Ga, or ~2 Gyrs after the Caloris basin formed.

242 t is experimentally verified in the (Fe(0.83)Ga(0.17))(100-x)Pt(x) (x = 0, 0.2, 0.4, 0.6, 0.8 and 1.0

243 nga Formation of the Mesoarchean (~2.96-2.84 Ga) Mozaan Group of the Pongola Supergroup of southern A

244 tflows of asymptotic giant branch stars <4.9 Ga ago that possibly formed during an episode of enhance

245 ted during the Early Noachian (~4.1 to ~3.94 Ga) when most Martian impact basins formed.

246 te that PVA achieves optimal H doping with a Ga...H distance of ~3.4 angstrom and conversion from six

247 ed-valence compounds containing Ga-arene and Ga-OTf coordination motifs, in addition to an unusual "n

248 promote the homogenous mixing of the Ca and Ga cations.

249 I)-bis-catechol and Ga(III)-bis-catechol and Ga(III)-(NE)(2) complexes by NMR spectroscopy reveals on

250 al analysis of PiuA Fe(III)-bis-catechol and Ga(III)-bis-catechol and Ga(III)-(NE)(2) complexes by NM

251 oretical techniques, including In K-edge and Ga K-edge extended X-ray absorption fine structure (EXAF

252 The fabrication of epitaxial beta-Ga(2)O(3) thin films is challenging on flexible substrat

253 band-edge luminescence is weak; hence, beta-Ga(2)O(3) has not been regarded as a promising material

254 Herein, beta-Ga(2)O(3) ([Formula: see text] 0 1) films are hetero-epi

255 We demonstrate that the nanocrystalline beta-Ga(2)O(3) films with 5% Ti significantly improves the re

256 However, the oxygen sensors based on beta-Ga(2)O(3) and other existing materials lack in response

257 iconductor-metal (MSM) photodetector on beta-Ga(2)O(3) layer shows an ultra-low dark current of 800 f

258 erest in the use of beta gallium oxide (beta-Ga(2)O(3)) as a semiconductor for high power/high temper

259 Monoclinic gallium oxide (beta-Ga(2)O(3)) is attracting intense focus as a material for

260 cal and optical characterization of the beta-Ga(2)O(3) nanowires including the optical bandgap and ph

261 muscovite mica which is the first time beta-Ga(2)O(3) epitaxy growth on any flexible substrate.

262 echanism that resembles the adhesion of bulk Ga drops to solid conductors.

263 the catalysis by the supramolecular capsule Ga(4)L(6)(12-) on the reductive elimination reaction fro

264 yl)phosphaketenes with the gallium carbenoid Ga(Nacnac) (Nacnac=HC[C(Me)N(2,6-i-Pr(2) C(6) H(3) )](2)

265 ll cases, mixed-valence compounds containing Ga-arene and Ga-OTf coordination motifs, in addition to

266 and conversion from six- to four-coordinate Ga, which together suppress deep trap defect localizatio

267 distances, Cu-Al = 2.3010(6) angstrom and Cu-Ga = 2.2916(5) angstrom.

268 Anisotropic Cu-Ga nanodimers, where the two segregated domains of the c

269 proach to design materials based on Ti-doped Ga(2)O(3), which exhibits a rapid response and excellent

270 g dopants incorporating substitutionally for Ga during growth of semi-polar facets of the hillock str

271 Our findings also suggest Ga(framework)-Ga(extra-framework) pairings, which can only be achieved

272 amined the performance of Cu(II)-, Fe(III)-, Ga(III)-, Ni(II)-, or Zn(II)-IMAC resins to reversibly b

273 p-type and remarkable n-type conductivity in Ga(2)O(3) which should usher in the development of Ga(2)

274 aging in addition to the standard imaging in Ga-68 PSMA PET/CT, particularly in patients presenting f

275 yers replacing state-of-the-art CdS in Cu(In,Ga)Se(2) thin-film solar cells, alternatives rarely exce

276 nature of an atomic-scale ordering of liquid Ga in contact with solid GaAs in a nanowire growth confi

277 upramolecular-organic framework (magOTfP5SOF-Ga(3+)) was designed for the one-step simultaneous enric

278 ped carbon (M(1)/CN, M = Pt, Ir, Pd, Ru, Mo, Ga, Cu, Ni, Mn).

279 n motifs, in addition to an unusual "naked" [Ga](+) ion, are found.

280 Three catalysts, Ni-Y, Ni-Lu, and Ni-Ga, showed nearly quantitative conversions in the semihy

281 length, ranging from 2.3395(8) angstrom (Ni-Ga) to 2.5732(4) angstrom (Ni-La).

282 ty in DPA hydrogenation follows the order Ni-Ga > Ni-La > Ni-Y > Ni-Lu > Ni-Sc.

283 In contrast, the Ni-Ga resting state is the Ni(eta(2)-H(2)) species, and Ni-

284 -based liquid metal electrodes, the nontoxic Ga alloys maintain high environmental benignity.

285 (3) which should usher in the development of Ga(2)O(3) devices and advance optoelectronics and high-p

286 of [Ga(arene)(n) ](+) salts on oxidation of Ga metal with AgOTf in arene solvents.

287 loring Lewis acid siting by the placement of Ga heteroatoms at distinct tetrahedral sites in the zeol

288 Herein, a series of Ga(3+)/Dy(3+) metallacrowns (MCs) is presented, demonstr

289 ) Ga NMR spectroscopy shows the presence of [Ga(arene)(n) ](+) salts on oxidation of Ga metal with Ag

290 the clathrate framework, a full ordering of {Ga or In} and Sb is observed by a combination of high-re

291 Here we report that 4-billion-year-old (Ga) carbonates in Martian meteorite, Allan Hills 84001,

292 ation analysis for the undoped and Al and/or Ga-doped LLZO variants uncovers an interplay between the

293 Gallium oxide (Ga(2)O(3)), one among the wide band gap oxides, exhibit

294 Our findings also suggest Ga(framework)-Ga(extra-framework) pairings, which can on

295 functional theory calculations, we show that Ga Lewis acid sites strongly favor aromatization.

296 resence of the native oxide shell around the Ga NPs and their liquid nature, via a mechanism that res

297 vanic replacement reaction (GRR) between the Ga seeds and a copper-amine complex takes place.

298 inding of guests in aqueous solution for the Ga(4)L(6) (12-) supramolecular construct.

299 (1,2) the synthesis of heavy elements in the Ga-Cd range in proton-rich neutrino-driven outflows of c

300 Here, highly conductive and transparent Ga doped ZnO thin films were grown via aerosol assisted